Edwards Lifesciences Corp. (EW): Price and Financial Metrics

Edwards Lifesciences Corp. (EW): $79.55

0.14 (+0.18%)

POWR Rating

Component Grades













EW POWR Grades

  • Quality is the dimension where EW ranks best; there it ranks ahead of 94.88% of US stocks.
  • The strongest trend for EW is in Stability, which has been heading down over the past 179 days.
  • EW ranks lowest in Value; there it ranks in the 34th percentile.

EW Stock Summary

  • EW has a higher market value than 95.55% of US stocks; more precisely, its current market capitalization is $48,306,166,776.
  • EW's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 824.87 -- higher than 96.38% of US-listed equities with positive expected earnings growth.
  • Price to trailing twelve month operating cash flow for EW is currently 39.65, higher than 89.15% of US stocks with positive operating cash flow.
  • If you're looking for stocks that are quantitatively similar to EDWARDS LIFESCIENCES CORP, a group of peers worth examining would be JKHY, KEYS, GLW, DOX, and STLA.
  • Visit EW's SEC page to see the company's official filings. To visit the company's web site, go to www.edwards.com.

EW Valuation Summary

  • In comparison to the median Healthcare stock, EW's price/sales ratio is 93.62% higher, now standing at 9.1.
  • EW's EV/EBIT ratio has moved down 0.2 over the prior 243 months.

Below are key valuation metrics over time for EW.

Stock Date P/S P/B P/E EV/EBIT
EW 2023-03-17 9.1 8.5 32.3 27.4
EW 2023-03-16 9.3 8.6 32.7 27.8
EW 2023-03-15 9.0 8.3 31.8 27.0
EW 2023-03-14 8.8 8.2 31.3 26.6
EW 2023-03-13 8.7 8.0 30.6 26.0
EW 2023-03-10 8.4 7.8 29.7 25.3

EW Growth Metrics

    Its 4 year net cashflow from operations growth rate is now at 90.86%.
  • Its 5 year revenue growth rate is now at 42.34%.
  • Its 2 year revenue growth rate is now at 19.48%.
Over the past 34 months, EW's revenue has gone up $898,700,000.

The table below shows EW's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 5,382.4 1,218.2 1,521.9
2022-09-30 5,363.8 1,309 1,458.8
2022-06-30 5,355 1,531 1,455.4
2022-03-31 5,357.1 1,724.9 1,538.5
2021-12-31 5,232.5 1,732.1 1,503.1
2021-09-30 5,094.5 1,758.5 1,477.3

EW's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • EW has a Quality Grade of B, ranking ahead of 92.8% of graded US stocks.
  • EW's asset turnover comes in at 0.681 -- ranking 53rd of 186 Medical Equipment stocks.
  • ATRS, SRDX, and ANGO are the stocks whose asset turnover ratios are most correlated with EW.

The table below shows EW's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.681 0.755 0.381
2021-03-31 0.647 0.752 0.229
2020-12-31 0.661 0.754 0.231
2020-09-30 0.678 0.755 0.235
2020-06-30 0.693 0.750 0.233
2020-03-31 0.744 0.744 0.370

EW Price Target

For more insight on analysts targets of EW, see our EW price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $119.36 Average Broker Recommendation 1.62 (Moderate Buy)

EW Stock Price Chart Interactive Chart >

Price chart for EW

EW Price/Volume Stats

Current price $79.55 52-week high $131.10
Prev. close $79.41 52-week low $67.13
Day low $78.88 Volume 2,701,200
Day high $81.16 Avg. volume 3,665,977
50-day MA $78.58 Dividend yield N/A
200-day MA $84.86 Market Cap 48.22B

Edwards Lifesciences Corp. (EW) Company Bio

Edwards Lifesciences is an American medical technology company headquartered in IrvineCalifornia, specializing in artificial heart valves and hemodynamic monitoring. It developed the SAPIEN transcatheter aortic heart valve made of cow tissue within a balloon-expandable, cobalt-chromium frame, deployed via catheter. The company has manufacturing facilities at the Irvine headquarters, as well as in DraperUtahCosta Rica; the Dominican RepublicPuerto Rico; and Singapore; and is building a new facility due to be completed in 2021 in LimerickIreland. (Source:Wikipedia)

EW Latest News Stream

Event/Time News Detail
Loading, please wait...

EW Latest Social Stream

Loading social stream, please wait...

View Full EW Social Stream

Latest EW News From Around the Web

Below are the latest news stories about EDWARDS LIFESCIENCES CORP that investors may wish to consider to help them evaluate EW as an investment opportunity.

5 big analyst cuts: Tesla stock slumps on Berenberg downgrade | Pro Recap

Tesla (NASDAQ:TSLA) shares fell 3% yesterday after Berenberg downgraded the company to Hold from Buy with a price target of $210.00 (from $200.00) as it believes the upside is limited following the year-to-date outperformance. Long-term, Berenberg remains bullish on the company and highlights the “significant” opportunity in the smaller vehicle segment. Etsy (NASDAQ:ETSY) shares fell more than 6% premarket today after Jefferies downgraded the company to Underperform from Buy and cut its price target to $85.00 from $150.00 as it believes the company's 70% valuation premium to Internet appears unsustainable given below average EBITDA growth and risk of downside to consensus.

Yahoo | March 9, 2023

HOLX or EW: Which Is the Better Value Stock Right Now?

HOLX vs. EW: Which Stock Is the Better Value Option?

Yahoo | March 7, 2023

Abbott (ABT) Makes Progress in the TAVI Space With Navitor

Results from Abbott's (ABT) PORTICO study support Navitor's recent FDA approval to treat patients with severe aortic stenosis who are at high or extreme risk for open-heart surgery.

Yahoo | March 7, 2023

Abbott's (ABT) MitraClip Device Shows Favorable Outcome

Abbott's (ABT) landmark COAPT trial demonstrated that MitraClip is safe and effective and can reduce the hospitalization rate.

Yahoo | March 7, 2023


Edwards Lifesciences (NYSE: EW) today highlighted new important data examining mortality rates and cardiac damage of early-stage aortic stenosis (AS) sufferers, along with data examining 10-year transcatheter aortic valve replacement (TAVR) re-intervention rates using real-world Medicare data. Together these studies, presented at the American College of Cardiology ACC.23/WCC, add valuable insights to the discussion on lifetime management of patients with AS.

Yahoo | March 6, 2023

Read More 'EW' Stories Here

EW Price Returns

1-mo 5.46%
3-mo 7.22%
6-mo -6.12%
1-year -27.33%
3-year 29.08%
5-year 76.36%
YTD 6.62%
2022 -42.41%
2021 42.00%
2020 17.32%
2019 52.31%
2018 35.90%

Continue Researching EW

Here are a few links from around the web to help you further your research on Edwards Lifesciences Corp's stock as an investment opportunity:

Edwards Lifesciences Corp (EW) Stock Price | Nasdaq
Edwards Lifesciences Corp (EW) Stock Quote, History and News - Yahoo Finance
Edwards Lifesciences Corp (EW) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7775 seconds.